Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 46,888 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 46,888 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44. Following the transaction, the chief executive officer now owns 15,298,896 shares of the company’s stock, valued at approximately $67,009,164.48. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Zaccardelli also recently made the following trade(s):

• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total value of $413,292.16.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Stock Up 0.6 %

Shares of VRNA opened at $38.39 on Wednesday. The business has a 50-day moving average of $31.07 and a 200-day moving average of $22.49. Verona Pharma plc has a 1 year low of $11.39 and a 1 year high of $39.40. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The firm had revenue of $5.62 million for the quarter, compared to analysts’ expectations of $2.31 million. During the same quarter in the prior year, the business earned ($0.18) EPS. Equities research analysts anticipate that Verona Pharma plc will post -2.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on VRNA shares. Wells Fargo & Company upped their price target on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday. HC Wainwright increased their target price on Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group boosted their price target on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Truist Financial raised their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $43.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC bought a new stake in Verona Pharma in the second quarter worth approximately $29,000. EMC Capital Management acquired a new stake in shares of Verona Pharma during the 2nd quarter worth approximately $38,000. GAMMA Investing LLC increased its stake in shares of Verona Pharma by 70.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after acquiring an additional 553 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after acquiring an additional 529 shares during the period. Finally, Legato Capital Management LLC bought a new position in Verona Pharma during the second quarter worth $154,000. 85.88% of the stock is owned by institutional investors and hedge funds.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.